Table 1: Clinical studies of curcumin use in Alzheimer’s disease.

Study IDStudy designSample sizeFollow-up periodCurcumin doseOther medicationMain findingsAdverse eventsCurrent status

Completed studies
 Baum et al. 2008 [28]Randomized, double-blind, placebo controlled366 months1 g/day or 4 g/dayGingko biloba standardized leaf extract 120 mg/day, other medication not reported No differences between curcumin and placeboNo differences between placebo and both curcumin dose groupsCompleted and published
 Ringman et al. 2012 [29]Randomized, double-blind, placebo controlled3624 weeks + 48 weeks open-label2 g/day or 4 g/dayAcetylcholinesterase inhibitors and memantine allowed No differences between curcumin and placeboNo differences between placebo and curcumin Completed and published
 Hishikawa et al. 2012 [30]Case study, open-label31 year100 mg/dayDonepezil (dose not reported) Increase in the NPI-Q scoreNot reportedCompleted and published
Ongoing trials
NCT00595582Open-label1024 months5.4 g/dayBioperidine All patients did not terminate the studyDyspepsia (20% of the sample)Completed
NCT01001637Randomized, double-blind, placebo controlled262 months4 g/day or 6 g/dayAllowed stable doses of concomitant medications Still recruiting
NCT01383161Randomized, double-blind, placebo controlled13218 months180 mg/dayPermitted only aspirin (81 mg/die) Still recruiting
NCT01811381Randomized, double-blind, placebo controlled8012 months800 mg/dayNot allowed treatment for cognitive impairment (i.e. cholinesterase inhibitor, memantine) < 6 months prior to study enrollment Recruiting will start in September 2013
ACTRN12613000681752Randomized, double-blind, placebo controlled20012 months500 mg/day for 2 weeks, then 1,000 mg/day for other 2 weeks and then 1500 mg/day onwardsNot allowed warfarinNot yet recruiting

Legend. Neuropsychiatric Inventory Questionnaire: NPI-Q.